Mizuho Increases Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Key Points

• Mizuho has raised its price target for Abbott Laboratories from $135.00 to $140.00, indicating a potential upside of 6.03% from the stock's previous close, while maintaining a "neutral" rating on the stock.
• Multiple analysts have recently upgraded Abbott Laboratories, with Jefferies Financial Group increasing its target to $145.00 and Morgan Stanley raising theirs to $137.00.
• Abbott Laboratories reported quarterly earnings of $1.26 per share, meeting expectations, with a revenue of $11.14 billion, showing a 7.4% increase compared to the same quarter last year.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price lifted by research analysts at Mizuho from $135.00 to $140.00 in a research note issued on Tuesday,MarketScreener reports. The brokerage presently has a "neutral" rating on the healthcare product maker's stock. Mizuho's target price points to a potential upside of 6.03% from the stock's previous close.

Other analysts have also issued reports about the company. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Morgan Stanley raised their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Wells Fargo & Company cut their price objective on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Finally, Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $146.17.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $132.04 on Tuesday. The stock has a market cap of $229.82 billion, a price-to-earnings ratio of 16.56, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock has a 50 day moving average price of $132.57 and a 200-day moving average price of $131.60. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the prior year, the business earned $1.14 EPS. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently added to or reduced their stakes in ABT. Edge Financial Advisors LLC lifted its position in shares of Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after buying an additional 81 shares during the period. Avanza Fonder AB lifted its position in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock worth $22,904,000 after buying an additional 655 shares during the period. Madrona Financial Services LLC lifted its position in shares of Abbott Laboratories by 9.7% during the 2nd quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock worth $235,000 after buying an additional 152 shares during the period. Janney Montgomery Scott LLC raised its position in Abbott Laboratories by 12.4% in the 2nd quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock valued at $91,109,000 after purchasing an additional 73,780 shares during the last quarter. Finally, SageView Advisory Group LLC boosted its holdings in Abbott Laboratories by 18.6% in the first quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock valued at $2,427,000 after acquiring an additional 2,873 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.